Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $1.2 million.

  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) rose 3835.77% to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.9 million, marking a year-over-year increase of 9074.72%. This contributed to the annual value of $4.6 million for FY2025, which is 9631.85% up from last year.
  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) amounted to $1.2 million in Q4 2025, which was up 3835.77% from $1.3 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $1.3 million for Q3 2025, and its period low was $479000.0 during Q3 2024.
  • Its 5-year average for Depreciation & Amortization (CF) is $797950.0, with a median of $748000.0 in 2021.
  • In the last 5 years, Enanta Pharmaceuticals' Depreciation & Amortization (CF) tumbled by 3448.72% in 2022 and then soared by 16805.85% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Depreciation & Amortization (CF) stood at $780000.0 in 2021, then tumbled by 34.49% to $511000.0 in 2022, then grew by 25.64% to $642000.0 in 2023, then surged by 38.47% to $889000.0 in 2024, then skyrocketed by 38.36% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q4 2025, $1.3 million for Q3 2025, and $1.2 million during Q2 2025.